Premium
Retraction Statement: ‘MicroRNA‐218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer’ by Li J, Wang J, Wang Y, Qiu H
Publication year - 2017
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12644
Subject(s) - hela , microrna , cell culture , cancer research , cervical cancer , cancer , chemistry , biology , genetics , biochemistry , gene
The above article from APMIS, published online on 24 April 2015 in Wiley Online Library ( wileyonlinelibrary.com ) and in Volume 123, pp. 562–570, has been retracted by agreement between the authors, the journal Editors in Chief, Professors Bodil Norrild, Ben Vainer and Elisabeth Ralfkiær, and John Wiley & Sons Ltd. The article has been retracted due to errors in the reported results. In this study, the authors used HeLa and SiHa cell lines to investigate the biological roles of miR‐218. However, subsequently it emerged that the two cell lines were contaminated in the laboratory by other unknown cell lines. When repeating the experiments, it was found that the functions of miR‐218 were not as significant as had been previously reported, especially its effects on rapamycin sensitivity. Reference Li J, Li X, Wang J, Wang Y, Qiu H. MicroRNA‐218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer. APMIS 2015; 123:562–570. doi: 10.1111/apm.12387 .